Roche Q3 Sales Rise 7% YoY At CER; 9M Group Sales Up 6% At CER To CHF 46.5B; Pharmaceuticals Up 7%, Diagnostics Up 4%
Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026Group sales were
Roche sold more medicines and tests this quarter, growing faster than before. When a company grows sales steadily, it can mean their products are working well and people need them.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.